The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
i think your find a lot of the trades over the last week have been the placement sold.
i also don't think it matters what price the shares have been sold out to raise the money.
yes someone may well be accumulating but at this ridiculous price why not.
but the ceo takes the biscuit for the second time for a very lazy placing.
he does not give a ****e about lth
Today another 2 x Million buys and accumalation must be happening. An agreement is needed to attract new investors, as Interim Results implied. If a leak now I will be disappointed. I did not average down after last RNS. We are waiting.
That big trade looks like bed and ISA?
Sell, probably by me. I'm out!
Is that 17k buy or sell 🤔!!!!
Deary me this is a shocking sp.......
Sounds good for Nanogenics.
They have been talking of investing in a new product for a long time now so i think it is premature to suggest that this small acquisition implies an issue or that they've given up with Nuvec.
Yes the acquisition appears cheap but from looking at the accounts of the seller it looks like they were v light in the cash department pre sale, hence maybe in a forced sale position. Older reports from 2018/19ish indicated that subsequent to previous lab work Nanogenics were then looking to list on the public market or progress via a new partner. Neither managed to get away so maybe to the next best option was progress the product via a partial sale to a listed vehicle (N4P).
It’s probable that exp105 will become the main product- it’s much closer to phase 1 trial.
However, why didn’t nanogenics progress the product themselves?
N4P has spent ages marketing and trialling Nuvec and now it just goes off and buys a company selling a totally separate RNA delivery method. IMO it makes no sense unless you've basically given up on Nuvec.
I would understand the purchase if it resulted in acquiring knowledge or tech to make Nuvec more effective somehow but it seems the only synergy is that maybe you can do testing for both systems at the same time. One system uses lipids to deliver RNA, the other silica nanomolecules IIRC. This purchase seems a distraction from focussing on Nuvec.
I also would have thought that Nanogenics could stand on its own two feet if it had a really good product and in that case it would be a much more expensive company to purchase. Can anyone explain what benefits this purchase does to help promote Nuvec?
Agreed, a fair presentation. Before anyone panics, Nigel’s apparent % reduction in his holding is because the placing adding extra shares to the share count. I dont actually remember a similar announcement from the 2p placing which would have had the same effect. I do sympathise with long term holders. Many false dawns, but this does look the most promising product so far. It is a slight concern that n4p lipid deal looks a bit too good to be true. It may simply be that the terms were better and fairer to both parties than anyone else was prepared to offer and that n4p are already connected with drug companies prepared to trial their delivery system, plus the research foundation with the university in Queensland. Positive, but still a lingering frustration
I like this presentation. It's excellent and a very a positive messaging platform to attract new investors and to remind existing shareholders of our true potential. There is a BUT though and it is this: having been invested in N4P for several years it is certainly a bit galling to read the following slide:
* Invest at early stage/ attractive valuation, in an siRNA product
which meets an unmet clinical need in the growing market of
ophthalmology
Message to Nigel Theobald: many have been doing just that for the last few years with N4P.
It's time to start delivering....
Good luck, Brighty
Https://www.n4pharma.com/wp-content/uploads/2023/09/N4-Pharma-Nanogencis-acquisition-1.pdf
GermanGrim
So sorry to hear this, i hope you make up your losses. If you have spare cash maybe try to invest in a different share altogether, but everything has a risk.
I am looking for the bottom here as i want to diversify. Currently just in one share at moment
Why the big drop here?
Thanks
GG
Thats a valid point. I've had a litle time to read up on the other delivery system, I initially assumed due to the name that it was going to be a liped base delivery wich can have some toxicity issues, so our product may have provided a benefit from that perspective.
However on doing a litle more reading liptide is a artificial virus delivery system, there is some lipeds involved but i belive this is primarly for the relase of the prodcut not the transition into the cell. Like N4p product its very interesting and is able to target specific areas. Liptide seems to do this via protien markers attached to it alwoing it to access/attach to certain cells for delivery.
I would have to go back on my original assumtion, it may be tested to see if it has higher efficancy for delivery but the delivery system seems to do the job.
So two product twice the chance?
The only concerning thing I have come across was the company talking about being in talks with other companys in 2017, but not sure what happened with that or why 6 yesrs later n4p can buy such a big share of the company for the price they got it for.
Sorry for the spelling, I'm on my phone and am very dyslexic.haha.
Nigel is a good communicator but not a engineer, scientist or doctor
As with all early stage entrepreneurs he has to convince investors to trust him in speculative tech
Unfortunately the reformulation division was a hopeless venture in which the main achievement was tens of patents for multiple reformulated generic drugs which the original pharma behemoths had no interest in reformulating themselves. Nigel was able to convince some of the people here that he could achieve something Pfizer et Al could not do. He hopelessly failed
To me the RNS explains adequately the difference between what Nuvec is being trialed for and what Nanogenic’s lipids is being trialed for. Very different diseases, for treatment in different organs with special requirements. There are billions of pounds being spent in the USA on nanotechnology all trying to provide similar therapies with different delivery systems to deliver toxic drugs in a safer and less intrusive way. This acquisition has doubled our chances of getting to commerciality in huge markets. Of course it may never happen and N4p may well die trying. The pandemic may have been a bit of a red herring as we have seen many companies collapsing in the aftermath . As we have seen in the news recently Covid is far from dying, and whatever people feel about vaccine they are going to continue to play a big part in our survival. Clearly Nigel is not an idiot. Whether he is successful or not is another matter. There a far more entrepreneurs that fail especially in this industry, but the ones that succeed are worth the weight in gold. That is the nature of this capitalist system for better or worse
Https://www.cynthiayuwaiman.com/about
The consultant ophthalmologist and scientist who developed EXP105
https://research.edgehill.ac.uk/ws/portalfiles/portal/37674038/pharmaceutics-13-00382.pdf
She is a scientific advisor to nanogenics- she is not on the board however. They estimate 15
Months to human trials- it’s unclear if this will be achieved- the original paper and positive findings date from 2016. However the delivery particle seems easy to manufacture without significant side effects- at least in the rabbit model
Pip13: but we have 2 delivery systems now. Where is the benefit? Is it that we can offer customers a choice between the 2?
GermanGrim..
I hold my head in my hands when I see such a post.
Not that I don't feel some sympathy, but why oh why do investors investors allow their capital to be run down so exorbitantly.
There are a multitude of points where there's a chance to get out with a minimal loss.
RNS after RNS indicated that this was going bad a few years ago... Especially after the Viagra fiasco.
You have to react to changing circumstances.
It's crazy to me to allow so much money to go down the plug-hole.
6-7yrs here, £32k in, average about 23p 😂, if I didn't laugh I'd cry.. the captains bottom drawer on the Titanic isn't even low enough for this🥴
Terrible.
Sorry but you raise 350k but you wipe over 30% plus off the market cap. Don't explain why.
Its aware this has been coming to people in the N4P inner circle. So its more like 40%
Must go to a different business school than the CEO.
Sometimes a deal offered to you has to taken there and then, it might not be good timing but we have secured another asset and it helps derisk our investment if they can show the proceeds are used to good effect.
Todays price isn’t ideal but it’s done, he now needs to convince shareholders it was the right decision.. I’m not overly bothered about writeups, broker notes or interviews.. We need to see collaborations for the new asset and a human trial plan for Nuvec (assuming oncology results are positive), nothing less.